Zydus Lifesciences has received a warning letter from the United States Food and Drug Administration (USFDA) concerning its Baddi manufacturing facility. The regulatory communication specifically flags issues related to purified talc that does not meet United States Pharmacopeia (USP) standards. Despite the regulatory action, the company has confirmed that its current operations and supplies remain unaffected.

USFDA Warning Letter: Key Details

The warning letter issued by the USFDA to Zydus Lifesciences pertains to the company's Baddi facility. The primary concern raised in the letter relates to purified talc failing to comply with the requisite USP standards. The following table summarizes the key details of the regulatory development:

Company's Clarification on Operational Impact

Zydus Lifesciences has stated that the warning letter does not impact its current operations or supplies. The company's clarification indicates that day-to-day manufacturing and distribution activities at the facility continue without disruption. The specific concern flagged by the USFDA is limited to purified talc not conforming to USP standards, and the company has not indicated any broader operational implications at this stage.

The USFDA warning letter represents a formal regulatory communication requiring the company to address the identified compliance gaps. Such letters typically necessitate a written response from the company outlining corrective and preventive actions to resolve the cited observations.

Zydus Lifesciences Limited has published the offer opening advertisement for its buyback of up to 87,30,158 equity shares at ₹1,260 per share for an aggregate amount of ₹1,100 crore. The offer is being conducted on a proportionate basis through the tender offer route using the stock exchange mechanism. The record date for determining eligibility is May 29, 2026, and the letter of offer was dispatched to eligible shareholders on June 2, 2026.

The buyback represents 0.87% of the total paid-up equity share capital. The revised buyback price of ₹1,260 per share marks an increase from the originally proposed ₹1,150, while the maximum number of shares repurchased has been reduced to 87,30,158. The offer is scheduled to open on June 4, 2026, and close on June 10, 2026. The Buyback Size represents 5.16% and 3.84% of the aggregate of the total paid-up equity share capital and free reserves of the company as per the latest audited standalone and consolidated financial statements as at March 31, 2026, respectively.

Buyback Parameters

The updated details of the buyback offer are as follows:

Entitlement Ratios

The buyback entitlement ratios for eligible shareholders are detailed below:

Shareholding and Process

The pre-buyback shareholding pattern shows the promoter and promoter group holding 74.99% of the total equity shares. Other major categories include foreign portfolio investors at 6.86% and insurance companies at 6.12%. The company has appointed ICICI Securities Limited as the manager to the buyback and MUFG Intime India Private Limited as the registrar. The last date for receipt of completed tender forms and other specified documents by the registrar is on or before 5:00 PM on Wednesday, June 10, 2026.